Stryker Corporation

SYK · Healthcare

$277.33
+0.13% today

What a holder would want to know before buying SYK: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.

Where the price sits
Low $269.75 · Sep 2026High $388.35 · Oct 2025

Today’s price is 3% above the lowest point of the past year and 29% below the highest.

Over the past year it was cheaper than today on 6% of days and more expensive on 94%. Over the last 10 years: cheaper on 68% of days.

16% below its average price of the last 200 trading days.

How bad does it get

Fell 20% or more 3 times in 10 years. The deepest fall was 44%; the longest took 17 months to get back to its peak. 2 of 3 have recovered so far.

It is in one now: 31% below the Jul 2025 peak.

Jul 2025
−33%not back yet
Sep 2021
−32%back in 17 months
Feb 2020
−44%back in 8 months
What you own

Stryker Corporation · Healthcare · Medical Devices · a large company worth $106.38B

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology…

Is it making money?
2022
2023
2024
2025

revenue profit

Sales of $25.12B in 2025, with $3.25B of profit. Sales grew in 3 of the last 3 years.

Keeps about 14 cents of every dollar of sales as profit.

Is it healthy?
Cash
$3.48B
Debt
$15.45B
Free cash flow / yr
$4.11B

Would need about 3.8 years of free cash flow to repay all its debt.

Is it expensive?

You pay $29 for every $1 of last year’s profit, and $17 for every $1 of profit expected next year.

A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.

Pays 1.27% a year in dividends at today’s price · next ex-dividend Sep 30.

What others are doing

29 analysts: 23 say buy, 6 hold, 0 sell. Their average 12-month target is $366.15 (range $298.00–$465.00).

Insiders made 0 purchases and 6 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.

Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.

Now try it without risking anything

Poshkan is paper trading: real prices, virtual money. Buy SYK with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.

Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.